Status:

NOT_YET_RECRUITING

Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)

Lead Sponsor:

Peking University Third Hospital

Collaborating Sponsors:

National Natural Science Foundation of China

Conditions:

Chronic Low Back Pain (CLBP)

Acute Low Back Pain

Eligibility:

All Genders

18-85 years

Brief Summary

This prospective cohort study investigates the neurobiological, genetic, and psychosocial mechanisms underlying acute and chronic low back pain (LBP). Core objectives include establishing a high-quali...

Detailed Description

Low back pain (LBP) is one of the leading causes of disability globally, yet its underlying mechanisms remain poorly understood. Clinical management is often challenging due to the heterogeneity in sy...

Eligibility Criteria

Inclusion

  • Adults aged 18 to 80 years.
  • Diagnosis of low back pain, defined as pain located between the lower costal margins and the gluteal folds, with or without leg pain.
  • Eligible for surgical or non-surgical treatments.
  • Willingness to undergo neuroimaging (fMRI), microbiota sampling, psychological assessments, and other related study procedures. Ability to provide written informed consent.

Exclusion

  • Severe neurological deficits requiring emergency surgery.
  • Antibiotic or probiotic use within the past 4 weeks. Suffering from digestive diseases such as irritable bowel syndrome, gastric ulcer, duodenal ulcer, etc.;
  • Diagnosed spinal infections, tumors, fractures, or inflammatory diseases (e.g., ankylosing spondylitis).
  • Known severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) that would interfere with study participation.Head trauma; history of substance abuse.
  • Contraindications to MRI scanning (e.g., pacemaker, metallic implants, severe claustrophobia).
  • Pregnant or breastfeeding women.
  • Participation in another interventional clinical trial within the past 3 months.
  • Working at night shifts or travelling across time zones in the past 6 months.
  • Excessive consumption of coffee, tea.

Key Trial Info

Start Date :

May 15 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

360 Patients enrolled

Trial Details

Trial ID

NCT06967363

Start Date

May 15 2025

End Date

December 31 2028

Last Update

May 13 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Peking university third hospital

Beijing, Beijing Municipality, China, 100000

2

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100191